Agomab Therapeutics announced that it has initiated a Phase 1 trial of its AGMB-447 inhaled ALK5 inhibitor that is expected to enroll 76 healthy subjects and idiopathic pulmonary fibrosis (IPF) patients. According to Agomab, the IPF patients will receive AGMB-447 over a two-week period following a SAD/MAD portion of the study in healthy subjects.
Agomab Chief Development Officer Andrea Sáez commented, “Starting clinical development for AGMB-447, our second ALK5 asset to enter the clinic, is exciting and a key milestone for Agomab, as it represents a step forward in providing a potential new treatment option for patients with IPF and other fibrotic lung diseases. Thanks to its lung-restricted distribution, AGMB-447 has the potential to potently, yet safely, block TGFb, a key fibrogenic pathway, selectively in the target tissue.”
Read the Agomab Therapeutics press release.
